Financials
- Fiscal year
- 2025
- Total assets
- €2.4m
- Loss
- -€1.2m
- Solvency
- -135.4%
Total assets▲ 2.3%
Net result
20192025
YUN
ActiveSummary
The computed 12-month bankruptcy probability of YUN is 4.9% (elevated). The 2025 annual accounts show negative equity (-€3.2m) and a net result of -€1.2m. Equity is shrinking by ~12.2% per year across the filed fiscal years. Its solvency ranks better than 5% of 84 sector peers (fiscal year 2025). The company has been active since 2011 and the Belgian State Gazette contains no insolvency or warning signals.
Overview
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
NACE 21209Business and other management consultancy NACE 70200Business consulting NACE 70220
#4 company by total assets in Niel, Manufacturing sector1 site
Size
€2.4mtotal assets 2025
- Staff
- 9.8 FTE
- Equity
- -€3.2m
- Loss
- -€1.2m
Structure
- Board
- 4 members
Accounts 17 d early1 of 14 deeds read
Why 35- Negative equity -€3.2m- Loss of €1.2m, the second in a row (FY 2025)- Liquidity: current ratio 0.18, cash €48,858, halved- Size: 9.8 FTE, total assets €2.4mShow the evidence
Checked score
Score 2025
35
/ 100
Weak
Probability in this band: 4.2% to 15.0%
Better than 10% of its sector peers (NACE 21, micro)
Performance against the sector, not lower risk
Financial strength · tick = 2024
Weak
Solvency
0=
equity -135.4% of total assets
Liquidity
3-10
short-term debt 127.0% · cash 2.0%
Profitability
0=
return on assets -50.4%
Bankruptcy probability, 12 months
4.9%
Elevated
0%0.5%1.5%4%10%≥ 25%
About 5 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: 1.8%lowest value
12-2024: 1.8%● 0.0% vs 11-2024lowest value
01-2025: 1.8%● 0.0% vs 12-2024lowest value
02-2025: 1.8%▲ +1.6% vs 01-2025
03-2025: 2.0%▲ +10.5% vs 02-2025
04-2025: 2.0%● 0.0% vs 03-2025
05-2025: 2.0%▲ +1.7% vs 04-2025
06-2025: 2.2%▲ +5.3% vs 05-2025
07-2025: 3.2%▲ +46.8% vs 06-2025
08-2025: 3.2%▲ +1.0% vs 07-2025
09-2025: 3.2%● 0.0% vs 08-2025
10-2025: 3.2%● 0.0% vs 09-2025
11-2025: 3.2%● 0.0% vs 10-2025
12-2025: 3.2%● 0.0% vs 11-2025
01-2026: 3.2%● 0.0% vs 12-2025
02-2026: 3.2%▲ +1.4% vs 01-2026
03-2026: 3.1%▼ -3.1% vs 02-2026
04-2026: 3.1%● 0.0% vs 03-2026
05-2026: 3.2%▲ +1.6% vs 04-2026
06-2026: 3.2%▲ +0.8% vs 05-2026
07-2026: 3.4%▲ +5.5% vs 06-2026
08-2026: 4.9%▲ +43.4% vs 07-2026highest value
09-2026: 4.9%● 0.0% vs 08-2026highest value
10-2026: 4.9%● 0.0% vs 09-2026highest value
- Negative equity -€3.2m raises the probability
- Loss of €1.2m, the second in a row (FY 2025) raises the probability
- Liquidity: current ratio 0.18, cash €48,858, halved raises the probability
- Size: 9.8 FTE, total assets €2.4m raises the probability for this profile
No credit on open account
Liquidity short (current ratio 0.18 against 0.35 in 2024; short-term debt: 127% and cash: 2% of total assets), and equity is negative.
How it is calculated
The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (NACE 21, micro). Better than this share of them on solvency 10%, liquidity 4%, profitability 12%, growth against the median 13%. That is performance, not lower risk; the band itself always comes from the probability.
Bankruptcy probability: model pd-v3.202610021621, computed on 03-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.
Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Six signals. The signal on the left, the evidence on the right.
+raises risk○neutral
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025Equity per financial year
19202122232425
2019 to 2025 · latest year -€3.2m
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 14-07-2026, 17 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
17 d early
2024
35 d early
2023
29 d early
2022
20 d early
2021
30 d early
2020
112 d early
2019
30 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 39 days before the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 3 July (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven monthsPosition in the running window
03-10-2026 today31-12-2026 close31-07-2027 deadline
- Annual accounts filedfiscal year 2025 · full…
- Reappointments: VERLINDEN Tom (bestuurder,gedelegeerd bestuurder) and…Appointments: Frank Verhavert Consult (director)…
- Annual accounts filedfiscal year 2024 · abbreviated…
Key points
- Risk: Negative equityfiscal year 2025: debts exceed assets -€3.2m View
- Risk: 7 loss-making years in a rowloss fiscal year 2025 -€1.2m View
- Caution: Among the weakest 5% on equitysector median €4.8m · 84 companies -€3.2m View
- Caution: Equity fell in 2025from -€2.0m to -€3.2m ▼ 59.4% View
- Positive: Always filed on timeaccounts within the deadline every year 8 years View
By topic
Board & ownership
- Board
- 4 members
Go to Board & ownership
Network & group
- Connected companies
- 6
Timeline
- Events
- 11
- Since
- 2017
- Next accounts
- by 31-07-2027
- 14-07-2026Annual accounts filed
- 31-03-2026Reappointments: VERLINDEN Tom (bestuurder,gedelegeerd bestuurder) and LEMBRECHTS…
- 26-06-2025Annual accounts filed
Company details
- Sites
- 1
- Legal form
- Public limited company
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21209
- Founded
- 28-07-2011
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What other support did companies like this one receive, and it did not?Subsidies How does this company compare with its sector?Sector benchmark
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.